Expert Commentary on the Product Profile of Enfortumab Vedotin Plus Pembrolizumab
ONCOLOGY spoke with Kirollos S. Hanna, PharmD, BCPS, BCOP, FACC, about the recent approval of enfortumab vedotin plus pembrolizumab. He discussed how the trial has significantly impacted the bladder cancer space and the improvement it has made to the …